ASX:SHL Full Year Results: Sonic Healthcare Posts Higher Revenue, Earnings and Dividends

Sonal Goyal

17 September 2026 03:40 AM AEST

ASX:SHL Full Year Results: Sonic Healthcare Posts Higher Revenue, Earnings and Dividends

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Sonic Healthcare reported FY26 Revenue of approximately $10.9 billion, up 13% on the prior year, for the twelve months ended 30 June 2026
Net profit for FY26 was $608.3 million, up 18%, while underlying NPAT rose 17% to $621 million
Underlying EBITDA increased 11% to $1.933 billion, supported by 5% organic revenue growth across the group
The company reported total dividends of $1.08 per share for FY26 and provided FY27 EBITDA guidance of $1.95 billion to $2.03 billion at constant currency

Sonic Healthcare Limited (ASX:SHL) is a global medical diagnostics company providing pathology and laboratory medicine, radiology and primary care services. This article reviews the company's FY26 full-year results, its core operations, sector context and developments shareholders are monitoring for FY27.

The share price was AUD 19.62 during the Trading session on 17 September 2026. The stock moved up by 0.41% during the trading session on 17 September 2026.

Company Business

Sonic Healthcare operates laboratory medicine and pathology services, diagnostic imaging and radiology, and primary care and corporate medical services across multiple countries, including Australia, Germany, Switzerland, the United Kingdom and the United States. The company's core pathology and laboratory medicine Business provides diagnostic testing services to hospitals, general practitioners, specialists and patients, supported by an extensive network of laboratories and collection centres. The company has grown its international footprint over time through a combination of organic growth and acquisitions, including recent expansion of its German operations. In the United States, the company has been undertaking an operating review and restructuring of its anatomical pathology operations aimed at improving profitability.

Sector Context

The medical diagnostics sector is shaped by Demand for pathology testing linked to population health trends, personalised and preventative healthcare, and referral volumes from primary care and hospital systems. Reimbursement settings for diagnostic services vary by jurisdiction, with regulatory bodies in Australia, Germany, Switzerland, the United Kingdom and the United States each setting pricing and funding frameworks relevant to laboratory and imaging providers. The sector has also seen continued consolidation activity, with larger diagnostics providers integrating acquired businesses to achieve operational synergies and scale benefits.

Recent Developments

Sonic Healthcare released its results for the full year ended 30 June 2026 to the ASX on 20 August 2026. Earlier in the financial year, the company reported first-half results for the six months ended 31 December 2025, disclosing 5% organic revenue growth, an EBITDA Margin improvement of 30 basis points, and reaffirmed full-year EBITDA guidance of $1.87 billion to $1.95 billion at constant currency at that time. During FY26, the company's German business reported strong revenue growth aided by acquisitions and integration synergies, while operations in Australia, Germany, Switzerland and the United Kingdom contributed to overall organic growth. The company also continued its operating review of United States anatomical pathology operations during the year.

Financial Performance

For FY26, Sonic Healthcare reported revenue of approximately $10.9 billion, an increase of 13% on the prior year, with organic revenue growth of 5%. Net profit for the year was $608.3 million, up 18%, while underlying net profit after tax increased 17% to $621 million. Underlying EBITDA rose 11% to $1.933 billion. Basic Earnings Per Share from continuing operations was $1.23, up from $1.07 in FY25. For the first half of FY26, the company had reported revenue of $5.445 billion, up 17%, net profit of $262 million, and an interim Dividend of $0.45 per share, up 2.3% on the prior corresponding period, franked at 60%. The company declared total dividends of $1.08 per share for FY26.

Risks to Consider

Sonic Healthcare's results and guidance point to risks including reimbursement and fee changes in overseas markets, with the company specifically flagging headwinds from fee reductions in Switzerland and contract delays in the United Kingdom as factors relevant to its FY27 outlook. Margin pressure in its United States operations and the execution of the ongoing anatomical pathology restructuring in that market are additional considerations. Labour cost inflation, currency movements across the company's multiple operating geographies, and integration risk associated with recent acquisitions, particularly in Germany, are also relevant to the business.

What to Watch Next

Sonic Healthcare has provided FY27 EBITDA guidance of $1.95 billion to $2.03 billion at constant currency, anticipating continued organic growth across its major markets, underpinned by demand for personalised and preventative healthcare. The company has flagged margin improvement expectations in Germany and Switzerland, alongside headwinds from Swiss fee cuts and United Kingdom contract delays. Shareholders are monitoring progress on the United States operating review and the company's half-year results for the six months to 31 December 2026.

Key Insights

Sonic Healthcare's FY26 results show double-digit growth in revenue, net profit and underlying EBITDA, supported by organic growth and recent acquisitions, particularly in Germany. The company has provided FY27 guidance that anticipates continued organic growth alongside specific headwinds in Switzerland and the United Kingdom. Progress on the United States restructuring and integration of recent acquisitions are among the factors likely to shape the company's performance in the year ahead.

FAQs

Q: What services does Sonic Healthcare provide?

A:Sonic Healthcare provides pathology and laboratory medicine, diagnostic imaging and radiology, and primary care and corporate medical services across Australia, Germany, Switzerland, the United Kingdom and the United States.

Q: What was Sonic Healthcare's revenue for FY26?

A:Sonic Healthcare reported revenue of approximately $10.9 billion for FY26, an increase of 13% on the prior year, with organic revenue growth of 5%.

Q: What was Sonic Healthcare's net profit for FY26?

A:Net profit for FY26 was $608.3 million, up 18% on the prior year, while underlying net profit after tax rose 17% to $621 million.

Q: What is Sonic Healthcare's FY27 guidance?

A:The company has provided FY27 EBITDA guidance of $1.95 billion to $2.03 billion at constant currency, anticipating continued organic growth across its major markets.

Q: What dividend did Sonic Healthcare declare for FY26?

A:Sonic Healthcare declared total dividends of $1.08 per share for FY26.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.